News
1d
TipRanks on MSNGSK Executives Acquire Shares Under Reward Plan
GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...
The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.
Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...
GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore ...
1d
TipRanks on MSNGSK Enhances Shareholder Value with Strategic Buyback
GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK plc has announced the purchase of 494,426 of its own ordinary shares as part of ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...
In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!
Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.
The FTSE 100 began Friday’s session on a positive note, gaining 23 points, reaching 9,124, as investors paid attention to ...
GlaxoSmithKline Pharmaceuticals Q1 net profit rises 12% to Rs 279 crore, despite slight dip in total income. Company highlights upcoming oncology drug launches.
GlaxoSmithKline Pharmaceuticals' shares fell by 2% in Thursday's morning trade, reflecting a bearish market sentiment. The company is currently trading at Rs 2,680.10 per share.
British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results